OMER icon

Omeros

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 50%
Negative

Positive
Seeking Alpha
2 hours ago
Omeros: Novo Nordisk Deal Highlights MASP-3 Alternative Pathway Targeting
Omeros Corporation maintaining a Strong Buy rating after securing a $2.1 billion partnership with Novo Nordisk for MASP-3 inhibitor zaltenibart. OMER's zaltenibart targets Paroxysmal Nocturnal Hemoglobinuria with a differentiated mechanism, offering potential safety and dosing advantages over existing complement inhibitors. Recent phase 2 data showed significant improvements in hemoglobin and LDH levels, supporting advancement into phase 3 trials for PNH and other rare blood/kidney disorders.
Omeros: Novo Nordisk Deal Highlights MASP-3 Alternative Pathway Targeting
Positive
Zacks Investment Research
yesterday
NVO, OMER Ink $2.1B Zaltenibart Deal to Bolster Rare Disease Portfolio
Novo Nordisk's $2.1 billion deal for Omeros' zaltenibart aims to strengthen its rare disease pipeline amid GLP-1 market headwinds.
NVO, OMER Ink $2.1B Zaltenibart Deal to Bolster Rare Disease Portfolio
Positive
Seeking Alpha
yesterday
Omeros: Novo Nordisk's Licensing Deal Sends Shares Soaring, Makes Bull Case
Omeros Corporation's stock surged over 150% after licensing zaltenibart to Novo Nordisk for $340M upfront, plus milestones and royalties. The deal provides OMER with critical funding, alleviating bankruptcy concerns and supporting operations through 2027 as it pursues FDA approval for narsoplimab. Zaltenibart's unique MASP-3 inhibition offers advantages in PNH, attracting NVO, which seeks to diversify beyond semaglutide amid recent headwinds.
Omeros: Novo Nordisk's Licensing Deal Sends Shares Soaring, Makes Bull Case
Neutral
Business Wire
yesterday
Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in Blood Advances, a journal of the American Society of Hematology, detailing survival outcomes in adult patients with life-threatening transplant-associated thrombotic microangiopathy (TA-TMA) treated with narsoplimab across both the pivotal clinical trial and the global expanded access program (EAP). Narsoplimab inhibits MASP-2, the effector enzyme of the lectin pathway of.
Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group
Positive
The Motley Fool
yesterday
A Deal With Novo Nordisk Sent This Stock 181% Higher Overnight. Is It a Buy Now?
Shares of Omeros (OMER 153.90%) finished Oct. 14's trading session at $4.10 per share. When the market opened on Oct. 15, the stock was up by 181% at $11.52 per share.
A Deal With Novo Nordisk Sent This Stock 181% Higher Overnight. Is It a Buy Now?
Positive
Benzinga
2 days ago
Omeros Stock Skyrockets After Novo Nordisk Strikes $2.1B Rare Disease Drug Deal
Biotech breakthroughs are reshaping the pharmaceutical landscape, sparking lucrative deals and redefining the future of rare disease treatment. Omeros Corporation (NASDAQ:OMER) stock is rallying on Wednesday, with a session volume of 89.21 million versus the average volume of 1.11 million, as per data from Benzinga Pro.
Omeros Stock Skyrockets After Novo Nordisk Strikes $2.1B Rare Disease Drug Deal
Neutral
Investors Business Daily
2 days ago
Omeros Catapults Almost 150% On A Surprise $2.1 Billion Deal With Novo Nordisk
Omeros stock catapulted Wednesday after Novo Nordisk agreed to pay up to $2.1 billion to license its experimental treatment.
Omeros Catapults Almost 150% On A Surprise $2.1 Billion Deal With Novo Nordisk
Positive
Invezz
2 days ago
Can OMER stock retain Novo Nordisk driven gains over the long-term?
Omeros Corporation (NASDAQ: OMER) opened over 150% up this morning after announcing a new licensing agreement worth up to $2.1 billion with the Bagsværd-headquartered Novo Nordisk. According to OMER's press release, this deal grants Novo exclusive global rights to develop and commercialise its MASP-3 inhibitor, zaltenibart (formerly OMS906), across all indications.
Can OMER stock retain Novo Nordisk driven gains over the long-term?
Positive
WSJ
2 days ago
Novo Nordisk to Pay Omeros Up to $2.1 Billion For Blood Disease Drug
Under the agreement, Novo Nordisk will be granted exclusive global rights to develop and commercialize zaltenibart.
Novo Nordisk to Pay Omeros Up to $2.1 Billion For Blood Disease Drug
Positive
Reuters
2 days ago
Novo Nordisk signs up to $2.1 billion licensing deal with Omeros in rare disease push
Danish drugmaker Novo Nordisk and Omeros have signed a licensing deal worth up to $2.1 billion for the U.S.-based company's experimental drug, which is being developed for rare blood and kidney disorders, they said on Wednesday.
Novo Nordisk signs up to $2.1 billion licensing deal with Omeros in rare disease push